Linked Life Data

18038273

Source:http://linkedlifedata.com/resource/pubmed/id/18038273

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-2-4
pubmed:abstractText
This 6-month randomized double-blind placebo-controlled trial shows that risedronate is well tolerated and effective in improving lumbar spine BMD and reducing loss of BMD at the hips in patients receiving high-dose prednisolone.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0937-941X
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
357-64
pubmed:dateRevised
2010-5-10
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
pubmed:affiliation
Department of Medicine and Nuclear Medicine, Tuen Mun Hospital, Tuen Mun, Hong Kong, SAR, China. ccmok2005@yahoo.com
pubmed:publicationType
Journal Article, Randomized Controlled Trial